SUMMARY To evaluate the role of the expression of hepatitis B core antigen (HBcAg) in liver cell damage the immunoperoxidase staining pattern of cryostat liver biopsy specimens from 16 chronic carriers of hepatitis B surface antigen (HBsAg) was investigated using three different kinds of antiHBc antibodies. Polyclonal antibody prepared from recombinant HBcAg seemed to be more sensitive in detecting HBcAg than did monoclonal antibody from the same antigen. The topographical distribution of HBcAg detected by these two antibodies was similar, showing a close correlation to the histological activity of disease. Furthermore, the predominant localisation of cytoplasmic HBcAg usually reflected an active and severe ongoing hepatitis. On the other hand, monoclonal antibody prepared from purified Dane particles resulted in the prominent cytoplasmic staining for HBcAg regardless of histological severity of the hepatitis. The quantitative expression and topographical distribution of HBcAg depended on the type of anti-HBc antibodies used.
Three different antigens have been identified in the sera of persons infected with hepatitis B virus: surface antigen, core antigen, and e antigen. Hepatitis B core antigen (HBcAg) exists on the core of Dane particles, and hepatitis B e antigen (HBeAg) is a protein separate from the other particulate antigens. The presence of HBeAg in the serum correlates with HBcAg as an antigenic marker of Dane particles' and a high reactivity for HBsAg-associated DNA polymerase which is contained in the core of Dane particles. 23 The presence of HBcAg in infected liver tissue is usually assumed to indicate ongoing virus replication.' Furthermore, HBcAg has been proposed as a possible immunological target for T cell mediated hepatocyte injury in chronic hepatitis B virus infection in experiments using autologous hepatocytes.9 Several investigators have attempted to correlate the distribution ofHBcAg in the hepatocytes with the extent of liver inflammatory activity, but the results remained inconclusive."8 HBcAg was principally seen within hepatocyte nuclei. A more recent study showed that cytoplasmic and membrane associated HBcAg was found to be more widespread Accepted for publication 6 October 1988 than suspected when an improved immunochemical method was used.'" Our previous study also showed that HBcAg was found mainly in the cytoplasm of hepatocytes in patients with type B chronic liver disease."
These findings led us to consider that the difference of antibodies used to determine the localisation of HBcAg might have been responsible for the disparate results. The method used might also be an important factor in influencing the sensitivity of detection. We conducted the present study with three different antibodies to HBcAg to evaluate the localisation of HBcAg in livers chronically infected with hepatitis B virus by staining cryostat sections with immunoperoxidase.
Material and methods
Sixteen patients with chronic hepatitis B virus infection were studied. Ten were seropositive for HBeAg and five were seropositive for anti-HBe. Histological diagnoses were made according to the criteria of an international group.'2 Of the 16 cases, 10 had chronic active hepatitis, four had chronic persistent hepatitis, and two had non-specific reactive hepatitis. Details of the patients studied are summarised in washing in PBS they were treated with normal goat serum for 10 minutes and followed by incubation with horseradish-peroxidase-conjugated goat F(ab')2 antimouse IgG diluted 1/80 or goat anti-rabbit IgG diluted 1/80 (TAGO Corporation, Burlingame, California) (second antibody), which had been absorbed to remove cross reactivity to human serum proteins at 4°C for 12 hours. After washing in PBS they were treated with diaminobenzidine solution containing hydrogen peroxidase for 10 minutes, counterstained with methyl green, dehydrated, and mounted. All reagents were previously absorbed against normal human liver. No staining was seen using negative control reagents such as normal mouse or rabbit serum in place of anti-HBc antibodies as the first antibody. There was no staining when polyclonal and monoclonal anti-HBc used here were preincubated with rHBcAg'3 or purified core particles.'" Each slide was coded and read by two independent observers on a light microscope. The expression of HBcAg was scored on a 0 to 4 scale corresponding to positivity in 0%, 1-10%, 1 -30%, 31-50%, > 50% of total hepatocytes examined.
The difference in the number ofhepatocytes positive for HBcAg between two groups of patients was compared using the Wilcoxon rank sum test. (table 2) . When 096D was used, HBcAg was almost equally detected in both the nuclei and cytoplasm in patients with non-specific reactive hepatitis and chronic persistent hepatitis; cytoplasmic expression of HBcAg was more prominent in patients with chronic active hepatitis (tables 1 and 2). Similar results were obtained for HBcAg distribution by BA8, although the sensitivity to detect HBcAg was lower in BA8 than in 096D. On the other hand, Hyb 3105 gave more prominent cytoplasmic staining of HBcAg even in patients with non-specific reactive hepatitis and chronic persistent hepatitis, and the sensitivity of Hyb 3105 for detecting HBcAg was similar to that of BA8.
Results

HBcAg in liver cells from 16 patients was found in 14
As shown in the figure, distinct patterns of HBcAg distribution and different numbers of HBcAg positive hepatocytes were seen when different anti-HBc antibodies (096D and Hyb 3105) were used for the frozen sections of the liver from an HBeAg positive patient with chronic persistent hepatitis (case 3).
Discussion
The results of this study have confirmed previous observations by others that there are various patterns of HBcAg distribution in the hepatocytes of patients with chronic hepatitis B virus infection.'°The important finding of this study is that the quantitative expression and topographical distribution of HBcAg depend on the anti-HBc antibodies used, although they are also closely related to the histological activity and to the antibody status of HBeAg/anti-HBe of the patients. 096D and BA8 antibodies are derived from the same immunising antigen, rHBcAg of Biogen SA, Switzerland.'3 096D is a polyclonal antibody raised in rabbits and BA8 is a monoclonal antibody. These two antibodies gave very similar staining for the topographical distribution of HBcAg, but 096D was more sensitive in detecting HBcAg than BA8. This finding suggests that the affinity of these antibodies to the corresponding epitopes may be different; polyclonal antibody could recognise plural antigenic determinants and then react more strongly with the corresponding antigen. The 
